Simcere Of China Says New Use Of Biotech Endu Favorable
This article was originally published in PharmAsia News
Executive Summary
China's Simcere Pharmaceuticals said its Endu, an endostatin biotech drug already approved for treating lung cancer, has demonstrated in interim results it is safe when used with platinum-containing chemotherapy. China's State FDA sought a re-evaluation of the drug before it would grant the new indication. Simcere said the new trial, expected to be completed in 2010, appears to show the drug is well-tolerated with chemotherapy. (Click here for more